Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 226

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia

Open access
Corte, Tamera J., Keir, Gregory J., Dimopoulos, Konstantinos, Howard, Luke, Corris, Paul A., Parfitt, Lisa, Foley, Claire, Yanez-Lopez, Monica, Babalis, Daphne, Marino, Philip, Maher, Toby M., Renzoni, Elizabeth A., Spencer, Lisa, Elliot, Charlie A., Birring, Surinder S., O’Reilly, Katherine, Gatzoulis, Michael A., Wells, Athol U., Wort, Stephen J. · 2014 · American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Pulmonary hypertension (PH) associated with fibrotic idiopathic interstitial pneumonia (IIP; idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia) confers important additional morbidity and mortality. OBJECTIVES: To evaluate the safety and clinical efficacy of the dual endothelin-1 receptor antagonist bosentan in this patient group. METHODS: In a randomized, double-blind, placebo-controlled study, 60 patients with fibrotic IIP and right heart catheter confirmed PH were randomized 2:1 to bosentan (n = 40) or placebo (n = 20). The primary study endpoint was a fall from baseline pulmonary vascular resistance index (PVRi) of 20% or more over 16 weeks. MEASUREMENTS AND MAIN RESULTS: Sixty patients (42 men; mean age, 66.6 ± 9.2 yr), with a mean pulmonary artery pressure of 36.0 (± 8.9) mm Hg, PVRi 13.0 (± 6.7) Wood Units/m(2) and reduced cardiac index of 2.21 (± 0.5) L/min/m(2) were recruited to the study. Accounting for deaths and withdrawals, paired right heart catheter data were available for analysis in 39 patients (bosentan = 25, placebo = 14). No difference in the primary outcome was detected, with seven (28.0%) patients receiving bosentan, and four (28.6%) receiving placebo achieving a reduction in PVRi of greater than or equal to 20% (P = 0.97) at 16 weeks. There was no change in functional capacity or symptoms between the two groups at 16 weeks, nor any difference in rates of serious adverse events or deaths (three deaths in each group). CONCLUSIONS: This study shows no difference in invasive pulmonary hemodynamics, functional capacity, or symptoms between the bosentan and placebo groups over 16 weeks. Our data do not support the use of the dual endothelin-1 receptor antagonist, bosentan, in patients with PH and fibrotic IIP. Clinical trial registered with www.clinicaltrials.gov (NCT 00637065).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201403-0446oc

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 226

Metadata

Authors
Corte, T. J., Keir, G. J., Dimopoulos, K., Howard, L., Corris, P. A., Parfitt, L., Foley, C., Yanez-Lopez, M., Babalis, D., Marino, P., Maher, T. M., Renzoni, E. A., Spencer, L., Elliot, C. A., Birring, S. S., O’Reilly, K., Gatzoulis, M. A., Wells, A. U., & Wort, S. J.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2014-07-15
Volume
190
Issue
2
Pages
208-217
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2158755381
Cited by
226
References
6
FWCI
15.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia. https://app.cochat.ai/papers/10.1164/rccm.201403-0446oc
The paper
Corte, T. J., Keir, G. J., Dimopoulos, K., Howard, L., Corris, P. A., Parfitt, L., Foley, C., Yanez-Lopez, M., Babalis, D., Marino, P., Maher, T. M., Renzoni, E. A., Spencer, L., Elliot, C. A., Birring, S. S., O’Reilly, K., Gatzoulis, M. A., Wells, A. U., & Wort, S. J. (2014). Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201403-0446oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.